MISSISSAUGA, ON, January 4, 2021 – MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that effective December 22, 2020, it closed the debt settlement announced in its Press Release dated December 22, 2020, pursuant to which it settled $65,000 of debt owed to an arm’s length professional adviser by issuance of 500,000 common shares. The shares issued on this debt settlement will be restricted from trading for four months from the date of issue.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecureTM telemedicine platform, utilizing its SIAscopyTM technology. SIAscopy is also imbedded in its products SIAMETRICSTM, SIMSYSTM, and MoleMateTM, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICSTM, SIMSYSTM, and MoleMateTM include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.


Rob von der Porten, Chairman and Acting CEO
MedX Health Corp